GPCM
TPTX

Granite Point Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Granite Point Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,700
Closed -$230K – 115
2019
Q4 		$230K Buy
+3,700
New +$176K 0.04% 84

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Granite Point Capital Management's TPTX Position: Q1 2020 in Review

Granite Point Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q1 2020, closing a stake of 3,700 shares — an estimated $230K sold.

Granite Point Capital Management first reported a position in TPTX in Q4 2019 and held it in 1 quarter. The position peaked at $230K in Q4 2019. 119 funds tracked by Wall St. Rank hold TPTX as of Q1 2020.

  • Granite Point Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Granite Point Capital Management sold 3,700 Turning Point Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $230K.
  • Granite Point Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Granite Point Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $230K in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Granite Point Capital Management's 13F filing for Q1 2020, filed 12 May 2020.